Aripiprazole as a potential pharmacotherapy for stimulant dependence: Human laboratory studies with d-amphetamine

Experimental and Clinical Psychopharmacology

Volumn 14, Issue 4, 2006, Pages 413-421

  Stoops, William W ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Amphetamine; Aripiprazole; Cocaine; Human; Pharmacotherapy; Stimulant dependence

Indexed keywords

ARIPIPRAZOLE; DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COCAINE DEPENDENCE; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; SUBSTANCE ABUSE;

ADULT; AMPHETAMINE-RELATED DISORDERS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DISCRIMINATION (PSYCHOLOGY); DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PIPERAZINES; PSYCHOMOTOR PERFORMANCE; QUINOLONES;

EID: 33751254731     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.14.4.413     Document Type: Article

References (63)

1. Beresford, T. P., Clapp, L., Martin, B., Wiberg, J. L., Alfers, J., & Beresford, H. F. (2005). Aripiprazole in schizophrenia with cocaine dependence: A pilot study. Journal of Clinical Psychopharmacology, 25, 363-366.
2. Bickel, W. K., & Kelly, T. H. (1988). The relationship of stimulus control to the treatment of substance abuse. In B. A. Ray (Ed.), Learning factors in substance abuse (pp. 122-140). Rockville, MD: U.S. Department of Health and Human Services.
3. Brauer, L. H., & de Wit, H. (1995). Role of dopamine in d-amphetamine-induced euphoria in normal, healthy volunteers. Experimental and Clinical Psychopharmacology, 3, 371-381.
4. Brauer, L. H., & de Wit, H. (1996). Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biological Psychiatry, 39, 26-32.
5. Brauer, L. H., & de Wit, H. (1997). High dose pimozide does not block amphetamine-induced euphoria in normal volunteers. Pharmacology Biochemistry and Behavior, 56, 265-272.
6. Brauer, L. H., Goudie, A. J., & de Wit, H. (1997). Dopamine ligands and the stimulus effects of amphetamine: Animal models versus human laboratory data. Psychopharmacology, 130, 2-13.
7. Bristol-Myers Squibb. (2002). Product information: Abilify, aripiprazole. Princeton, NJ: Author.
8. Brown, E. S., Jeffress, J., Liggin, J. D., Garza, M., & Beard, L. (2005). Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. Journal of Clinical Psychiatry, 66, 756-760.
9. 2 receptors. Journal of Pharmacology and Experimental Therapeutics, 302, 381-389.
10. Centorrino, F., Fogarty, K. V., Cimbolli, P., Salvatore, P., Thompson, T. A., Sani, G., et al. (2005). Aripiprazole: Initial clinical experience with 142 hospitalized psychiatric patients. Journal of Psychiatric Practice, 11, 241-247.
11. Childress, A. R., & O'Brien, C. P. (2000). Dopamine receptor partial agonists could address the duality of cocaine craving. Trends in Pharmacological Science, 21, 6-9.
12. de Wit, H., & Stewart, J. (1981). Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology, 75, 134-143.
13. di Marino, M. E., Haberny, K. A., Felch, L. J., Walsh, S. L., Preston, K. L., & Bigelow, G. E. (1998). Development of a subjective rating scale sensitive to acute cocaine administration. In Problems of drug dependence, 1997: Proceedings from the 59th Annual Scientific Meeting of the College on Problems of Drug Dependence (p. 139). Bethesda, MD: National Institute on Drug Dependence.
14. Drug Abuse Warning Network. (2004). Major drugs of abuse in ED visits, 2002 Update. Retrieved September 20, 2006, from http://dawninfo.samhsa.gov/ old_dawn/pubs_94_02/shortreports/
15. Drug and Alcohol Services Information System. (2006). Trends in methamphetamine/amphetamine admissions to treatment, 1993-2003. Retrieved April 3, 2006, from http://oas.samhsa .gov/2k6/methTx/methTX.cfm
16. 2 dopamine receptor agonists in rats discriminating d-amphetamine from saline. Behavioural Pharmacology, 3, 609-619.
17. Foltin, R. W., & Fischman, M. W. (1991). Assessment of abuse liability of stimulant drugs in humans: A methodological survey. Drug and Alcohol Dependence, 28, 3-48.
18. Gonzalez-Castro, F., Barrington, E. H., Walton, M. A., & Rawson, R. A. (2000). Cocaine and methamphetamine: Differential addiction rates. Psychology of Addictive Behaviors, 14, 390-396.
19. Grabowski, J., Shearer, J., Merrill, J., & Negus, S. S. (2004). Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addictive Behavior, 29, 1439-1464.
20. Griffiths, R. R., Bigelow, G. E., & Ator, N. A. (2003). Principles of initial experimental drug abuse liability assessment in humans. Drug and Alcohol Dependence, 70, S41-S54.
21. Gunne, L., Anggard, E., & Jonsson, L. (1972). Clinical trials with amphetamine-blocking drugs. Psychiatria, Neurologia, Neurochirurgia, 75, 225-226.
22. Hart, C. L., Haney, M., Foltin, R. W., & Fischman, M. W. (2002). Effects of the NMDA antagonist memantine on human methamphetamine discrimination. Psychopharmacology, 164, 376-384.
23. Hoffman, B. B. (2001). Catecholamines and sympathomimetic drugs, and adrenergic receptor antagonists. In J. G. Hardman & L. E. Limbird (Eds.) & A. G. Gilman (Consulting Ed.), Goodman & Gilman's The pharmacological basis of therapeutics (pp. 215-268). New York: McGraw-Hill.
24. Izzo, E., Orsini, C., Koob, G., & Pulvirenti, L. (2001). A dopamine partial agonist and antagonist block amphetamine self-administration in a progressive-ratio schedule. Pharmacology Biochemistry and Behavior, 68, 701-708.
25. Jacobs, D., & Silverstone, T. (1986). Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychological Medicine, 16, 323-329.
26. Jasinski, D. (1977). Assessment of the abuse potentiality of morphine like drugs (methods used in man). In W. R. Martin (Ed.), Drug addiction I (pp. 197-258). New York: Springer-Verlag.
27. Johanson, C. E., Frey, K. A., Lundahl, L. H., Keenan, P., Lockhart, N., Roll, J., et al. (2006). Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology, 185, 327-338.
28. Johnson, B. A., Roache, J. D., Ait-Daoud, N., Wallace, C., Wells, L., Dawes, M., & Wang, Y. (2005). Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects. International Journal of Neuropsychopharmacology, 8, 203-213.
29. Johnson, B. A., Roache, J. D., Ait-Daoud, N., Wallace, C., Wells, L. T., & Wang, Y. (2005). Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition. Psychopharmacology, 178, 296-302.
30. Johnson, B. A., Roache, J. D., Ait-Daoud, N., Wells, L. T., Wallace, C. L., Dawes, M. A., et al. (in press). Effects of acute topiramate dosing on methamphetamine-induced subjective mood. International Journal of Neuropsychopharmacology.
31. Johnson, B. A., Wells, L. T., Roache, J. D., Wallace, C., Ait-Daoud, N., & Wang, Y. (2005). Isradipine decreases the hemodynamic response of cocaine and methamphetamine: Results from two human laboratory studies. American Journal on Hypertension, 18, 813-822.
32. Johnston, L. D., O'Malley, P. M., Bachman, J. G., & Schulenberg, J. E. (2004). Monitoring the future: National survey results on drug use, 1975-2003: Vol. 1. Secondary school students (NIH Publication No. 04-5507). Bethesda, MD: National Institute on Drug Abuse.
33. Jonsson, L. (1972). Pharmacological blockade of amphetamine effects in amphetamine dependent subjects. European Journal of Clinical Pharmacology, 4, 206-211.
34. 1A receptor. European Neuropsychopharmacology, 11, S268.
35. Kelly, T. H., Stoops, W. W., Perry, A. S., Prendergast, M. A., & Rush, C. R. (2003). Clinical neuropharmacology of drugs of abuse: A comparison of drug-discrimination and subject report measures. Behavioral and Cognitive Neuroscience Reviews, 2, 227-260.
36. Lile, J. A., Stoops, W. W., Vansickel, A. R., Glaser, P. E. A., Hays, L. R., & Rush, C. R. (2005). Aripiprazole attenuates the discriminative- stimulus effects of d-amphetamine in humans. Neuropsychopharmacology, 30, 2103-2114.
37. Lile, J. A., Stoops, W. W., Wagner, F. P., Glaser, P. E., & Rush, C. R. (2005). Oxazepam does not modulate the behavioral effects of d-amphetamine in humans. Pharmacology Biochemistry and Behavior, 82, 270-279.
38. Martin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971). Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clinical Pharmacology and Therapeutics, 12, 245-258.
39. McLeod, D. R., Griffiths, R. R., Bigelow, G. E., & Yingling, J. E. (1982). An automated version of the Digit Symbol Substitution Test (DSST). Behavioral Research Methods and Instruments, 14, 463-466.
40. 1A agonists. Behavioural Pharmacology, 5, 591-598.
41. Natesan, S., Reckless, G. E., Nobrega, J. N., Fletcher, P. J., & Kapur, S. (2006). Dissociation between in vivo occupancy and functional antagonism of dopamine D(2) receptors: Comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology, 31, 1854-1863.
42. National Household Survey on Drug Abuse. (1994). NHSDA, Advance Report No. 10. Retrieved September 20, 2006, from http://oas.samhsa.gov/p0000016. htm#1994
43. National Survey on Drug Use and Health. (2004). Results of the 2003 National Survey on Drug Use and Health. Retrieved November 29, 2004, from http://oas.samhsa.gov/nhsda/ 2k3nsduh/2k3Overview.htm#toc
44. National Survey on Drug Use and Health. (2005). Methamphetamine use, abuse, and dependence. Retrieved April 3, 2006, from http://oas.samhsa.gov/2k5/ meth/meth.cfm
45. Newton, T. F., De La Garza, R., II, Fong, T., Chiang, N., Holmes, T. H., Bloch, D. A., et al. (2005). A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. Pharmacology Biochemistry and Behavior, 82, 704-711.
46. Newton, T. F., Roache, J. D., De La Garza, R., II, Fong, T., Wallace, C. L., Li, S. H., et al. (2005). Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology, 182, 426-435.
47. Newton, T. F., Roache, J. D., De La Garza, R., II, Fong, T., Wallace, C. L., Li, S. H., et al. (2006). Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology, 31, 1537-1544.
48. Nielsen, E. B., & Jepsen, S. A. (1985). Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs. European Journal of Pharmacology, 111, 167-176.
49. Nurnberger, J. I., Jr., Simmons-Alling, S., Kessler, L., Jimerson, S., Schreiber, J., Hollander, E., et al. (1984). Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man. Psychopharmacology, 84, 200-204.
50. Oliveto, A. H., Bickel, W. K., Hughes, J. R., Shea, P. J., Higgins, S. T., & Fenwick, J. W. (1992). Caffeine drug discrimination in humans: Acquisition, specificity and correlation with self-reports. Journal of Pharmacology and Experimental Therapeutics, 261, 885-889.
51. Parsons, L. H., Koob, G. F., & Weiss, F. (1995). Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. Journal of Pharmacology and Experimental Therapeutics, 274, 1182-1191.
52. Rawson, R. A., Anglin, M. D., & Ling, W. (2002). Will the methamphetamine problem go away? Journal of Addictive Disorders, 21, 5-19.
53. Rawson, R. A., Gonzales, R., & Brethen, P. (2002). Treatment of methamphetamine use disorders: An update. Journal of Substance Abuse Treatment, 23, 145-150.
54. Rothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D. V., Rice, K. C., Carroll, F. I., & Partilla, J. S. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse, 39, 32-41.
55. Rush, C. R., Stoops, W. W., Hays, L. R., Glaser, P. E. A., & Hays, L. S. (2003). Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. Journal of Pharmacology and Experimental Therapeutics, 306, 195-204.
56. Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L. X., Sibley, D. R., et al. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 28, 1400-1411.
57. Silverstone, T., Fincham, J., Wells, B., & Kyriakides, M. (1980). The effect of the dopamine receptor blocking drug pimozide on the stimulant and anorectic actions of dextroamphetamine in man. Neuropharmacology, 19, 1235-1237.
58. Stoops, W. W., Lile, J. A., Glaser, P. E. A., & Rush, C. R. (2006). A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug and Alcohol Dependence, 84, 206-209.
59. Stoops, W. W., Staton Tindall, M., Havens, J. R., Oser, C. B., Webster, J. M., Mateyoke-Scrivner, A., et al. (2006). Kentucky rural stimulant use: A comparison of methamphetamine and other stimulant users. Manuscript submitted for publication.
60. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Franceschi, D., Sedler, M., et al. (2001). Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. Journal of Neuroscience, 21, 9414-9418.
61. Wachtel, S. R., Ortengren, A., & de Wit, H. (2002). The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug and Alcohol Dependence, 68, 23-33.
62. Walsh, S. L., Geter-Douglas, B., Strain, E. C., & Bigelow, G. E. (2001). Enadoline and butorphanol: Evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. Journal of Pharmacology and Experimental Therapeutics, 299, 147-158.
63. Weiss, F., Markou, A., Lorang, M. T., & Koob, G. F. (1992). Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Research, 593, 314-318.